Health System

Latest News


Latest Videos


More News

Jessica Allegretti, MD, MPH.

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.

Screenshot of Jawad Saleh, PharmD, during a video interview

There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.